Figure 6.
Origin of dominant clones within each T-cell subset at week 12 of IL-2 therapy. (A) Correlation coefficients between the productive frequencies of the top 1000 clones at week 12 and the productive frequencies of the same clones at baseline (week 0) for each cell type are shown for an HD (gray filled circles) and patients (black dots). Each dot represents the correlation coefficient for an individual patient. Box plots depict the 75th percentile, median, and 25th percentile values; whiskers represent maximum and minimum values, except for outliers. The correlation coefficients for CD4Tregs were significantly lower than for CD4Tcons (P = .039) and CD8 T cells (P = .0005). (B) Origin of the dominant 1000 clones at week 12 (W12) in clinical responders (n = 6; patients 1, 4, 5, 8, 10, 11) vs nonresponders (n = 6, patients 2, 3, 6, 7, 9, 11). For each cell type, bar graphs show the percentage of dominant week 12 clones that were detected (blue) at baseline (W0) and the percentage of dominant week 12 clones that were not detected (orange) at baseline. Each column represents an individual patient. Two-sided Wilcoxon signed-rank test was used to assess significance.

Origin of dominant clones within each T-cell subset at week 12 of IL-2 therapy. (A) Correlation coefficients between the productive frequencies of the top 1000 clones at week 12 and the productive frequencies of the same clones at baseline (week 0) for each cell type are shown for an HD (gray filled circles) and patients (black dots). Each dot represents the correlation coefficient for an individual patient. Box plots depict the 75th percentile, median, and 25th percentile values; whiskers represent maximum and minimum values, except for outliers. The correlation coefficients for CD4Tregs were significantly lower than for CD4Tcons (P = .039) and CD8 T cells (P = .0005). (B) Origin of the dominant 1000 clones at week 12 (W12) in clinical responders (n = 6; patients 1, 4, 5, 8, 10, 11) vs nonresponders (n = 6, patients 2, 3, 6, 7, 9, 11). For each cell type, bar graphs show the percentage of dominant week 12 clones that were detected (blue) at baseline (W0) and the percentage of dominant week 12 clones that were not detected (orange) at baseline. Each column represents an individual patient. Two-sided Wilcoxon signed-rank test was used to assess significance.

Close Modal

or Create an Account

Close Modal
Close Modal